French mental health diagnostics company Alcediag announced the results of a study that identified six blood biomarkers as major hallmarks of bipolar disorder.
Alcediag said in a press release that its 410-subject study, published in Nature’s Translational Psychiatry, resulted in a reliable and accurate test capable of differentiating the depressive phases of bipolar disorder from unipolar depression.
This test, with high diagnostic performance, specificity and sensitivity greater than 80%, was facilitated by the combined use of RNA editing and artificial intelligence, the company said.